Status:
COMPLETED
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same fo...
Eligibility Criteria
Inclusion
- Male or female aged 18 to 65 years
- A documented diagnosis of major depressive disorder
Exclusion
- Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment
- Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the patient's current psychiatric status
- Patients whose current episode of depression exceeds 12 months or is less than 4 weeks prior to enrolment
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00351169
Start Date
May 1 2006
End Date
June 1 2007
Last Update
December 22 2008
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Edmonton, Alberta, Canada
2
Research Site
Kelowna, British Columbia, Canada
3
Research Site
Penticton, British Columbia, Canada
4
Research Site
Vancouver, British Columbia, Canada